Related Experiment Video

Updated: May 23, 2026

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)
08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)

Published on: May 16, 2012

Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening

Kimberly Brown Dahlman1, Joel S Parker, Tambudzai Shamu

  • 1Human Oncology and Pathogenesis Program, Sloan-Kettering Cancer Center, New York, New York, United States of America.

Plos One
|April 18, 2012
PubMed

Insights

Identifying new prostate cancer drug targets is crucial as current therapies fail. A gene screen revealed four targets that, when silenced, inhibit cancer growth and enhance antiandrogen effectiveness.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Current prostate cancer treatments, including hormone therapies, often lead to drug-resistant castration-resistant prostate cancer.
  • There is a critical need for novel therapeutic targets to overcome treatment resistance and improve patient outcomes.

Purpose of the Study:

  • To functionally identify genes that, upon silencing, reduce prostate cancer cell proliferation or induce cell death.
  • To discover genes that can enhance the efficacy of antiandrogen therapies in prostate cancer.

Main Methods:

  • Utilized an RNA interference-based short hairpin RNA (shRNA) barcode screen in LNCaP human prostate cancer cells.
  • Validated candidate genes through silencing to assess their impact on cell growth and response to antiandrogens.

Main Results:

  • Identified and validated four candidate genes (AKT1, PSMC1, STRADA, and TTK) that significantly impaired growth when silenced.
  • Demonstrated that silencing these genes enhanced the antiproliferative effects of antiandrogens in androgen receptor-positive prostate cancer cells.
  • Pharmacologic inhibition of AKT1, combined with antiandrogens, induced apoptosis, highlighting PI3K/AKT and androgen receptor (AR) pathway crosstalk.

Conclusions:

  • shRNA library screening is a valuable strategy for identifying novel drug targets in prostate cancer.
  • The identified genes (AKT1, PSMC1, STRADA, TTK) represent promising candidates for developing new therapeutic approaches against castration-resistant prostate cancer.
  • Targeting the PI3K/AKT pathway in conjunction with antiandrogens may overcome treatment resistance in prostate cancer.

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells09:12

MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells

Published on: December 21, 2011

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...